Muzzy Family Endowed Fellowship in Molecular Imaging and Therapy

This one (1) year program will provide a broad clinical experience in all aspects of molecular imaging and therapy, including:

• FDA-approved PET radiotracers (FDG, 68Ga-Dotatate, 64Cu-Dotatate, Pylarify, Cerianna, Axumin)
• Investigational PET radiotracers (targeting PSMA, ER, FAP, CD8, CD38, Amyloid, Tau, and others)
• FDA-approved radionuclide therapies (Pluvicto, Lutathera, Radioiodine)
• Investigational radionuclide therapies (targeting PSMA, FAP, SSTR, and others, including 225Ac alpha therapies)
• PET/CT and PET/MR
• General nuclear medicine
• Basic principles of radiotracers, radiopharmacy, and radiation safety.

The program director ensures rotation responsibilities do not detract from a fellow’s overall educational experience. The allocation of fellowship time will be scheduled in advance and in collaboration with the fellow.

• 40% Clinical service for PET/CT, PET/MR
• 40% Clinical service in the Molecular Imaging & Therapy clinic
• 20% Clinical investigation. Each fellow will be mentored on an original research project with the goal of national/international presentation and publication.

• Weekly didactics covering FDG PET/CT of all organ systems and specialized lectures covering each targeted imaging and therapy application.
• The fellow will attend an annual PET/CT and Molecular Imaging and Therapy course.
• Travel accommodations and reimbursements are granted for the fellow to attend the annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference and the Radiological Society of North America (RSNA) conference.
• If a fellow’s research project is accepted for presentation at a major radiology or molecular imaging meeting, the research fund will cover reasonable expenses and time to attend will be granted after coordination with and approval by the program director.
• Visiting Professorships: Through the Hoag Foundation Visiting Professorship Fund, nationally acclaimed physicians are brought to Hoag as guest speakers. Fellows are encouraged to attend these lectures.

• 3 PET/CT scanners: Biograph 64 Vision 450; Biograph mCT Flow; Biograph Truepoint
• 1 PET/MR Scanner: Biograph mMR
• 3 SPECT/CT scanners: all Symbia T
• 5 additional nuclear cameras
• Full Molecular Imaging and Therapy clinic with 3 lead lined therapy rooms, radiopharmacy, and office space

Current Clinical Trials at the Hoag Molecular Imaging and Therapy clinic include:

1. Estrogen Receptor (ER)-targeted imaging with 18F-fluoroestradiol
2. CD38-targeted imaging of myeloma with 89Zr-daratumumab
3. CD8-targeted immunoPET with 89Zr-crefmirlimab berdoxam
4. HER2-targeted imaging with 89Zr-pertuzumab
5. PSMA-targeted therapy with 177Lu-PSMA I&T
6. SSTR-targeted therapy with 225Ac-Dotatate

Salary and Benefits

• Annual salary of $100,000
• Benefits include medical/vision/dental insurance, professional liability coverage, disability coverage, and 4 weeks of vacation and conference time.

Program Length
1 year (August 1st – July 31st)

Available Positions
There is one (1) position available for the 2025-2026 academic year.

Diversity, Equity, and Inclusion
At Hoag, we know that a diverse, inclusive workplace is essential to our guiding mission: to serve our communities by providing health care services of the highest quality. We are committed to:

• Maintaining a diverse workforce that reflects our communities,
• Ensuring an inclusive workplace in which employees feel valued, respected, and able to fully contribute toward Hoag’s mission; and,
• Meeting the needs of our diverse communities.

Candidate Requirements
Applicants must have completed a nuclear medicine or diagnostic radiology residency at an ACMGE accredited program and be either board-eligible or board-certified by the American Board of Nuclear Medicine or The American Board of Radiology. Applicants must be eligible to obtain an unrestricted California medical license prior to the beginning of the Fellowship. We are unable to provide J-1 visa sponsorship at this time.

View the requirements for a California medical license. 

How to Apply
Candidates will be selected based on their clinical and imaging training, research experience, and letters of recommendation.

Application Materials

• Application Form 
• Curriculum Vitae: Please include honors, award, & publications on your curriculum vitae
• A personal statement that describes your: reasons for interest in molecular imaging, training expectations, and practice expectations. Do not exceed one page in length, single spaced, with one-inch margins.
• Three (3) letters of recommendation – one letter must be from your residency Program Director
• Copies of:
  • USMLE/COMLEX Score Reports
  • Medical School Diploma
  • ECFMG certificate if applicable

Email your application documentation to: fellowships@hoag.org

Hoag’s Molecular Imaging & Therapy fellowship follows the SCARD interview embargo program for recruitment for Radiology Sub-Specialties that do not participate in the Match.

Core Faculty and Program Director: Gary A. Ulaner, MD, PhD, FACNM, FSNMMI

Double Boarded Diagnostic Radiologist and Nuclear Medicine Physician

Gary A. Ulaner, MD, PhD, FACNM, FSNMMI, is the Director of Molecular Imaging and Therapy at Hoag Family Cancer Institute and the James & Pamela Muzzy Endowed Chair of Molecular Imaging and Therapy.

Dr. Ulaner joined Hoag following 10 years as faculty at Memorial Sloan Kettering Cancer Center. Dual board-certified in radiology and nuclear medicine, Dr. Ulaner is a nationally recognized expert in the use of targeted imaging to help direct targeted cancer therapies. He leads several National Institutes of Health (NIH) clinical trials in molecular imaging and therapeutics, including two active NIH R01 grants, and has received more than $8 million in extramural funding. His current active funded research includes estrogen receptor (ER)-targeted imaging and HER2-targeted imaging for patients with breast cancer, multiple prostate specific membrane antigen (PSMA)-targeted agents for imaging and treatment of prostate cancer, somatostatin receptor (SSTR)-targeted alpha therapy of neuroendocrine tumors, and CD38-targeted imaging for myeloma.

Dr. Ulaner has received multiple honors throughout his career. He was elected Fellow of the American College of Nuclear Medicine (ACNM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI), has given Grand Rounds lectures nationally and internationally, was named an Orange County “Healthcare Visionary”, and received multiple teaching and mentoring awards from Memorial Sloan Kettering, Cornell, and others.

Dr. Ulaner has authored or co-authored more than 150 peer-reviewed manuscripts, has given more than 200 national and international presentations, and authored the textbook Fundamentals of Oncologic PET/CT, published in both English and Spanish. He organizes and runs an annual 3-day PET/CT and Molecular Imaging CME course. He is also on the editorial boards of 5 leading clinical journals: Radiology, Journal of Nuclear Medicine, European Journal of Nuclear Medicine and Molecular Imaging, Clinical Nuclear Medicine, and Theranostics.

Dr. Ulaner completed his medical degree and a Ph.D. in Cancer Biology at Stanford University School of Medicine, an internship at Johns Hopkins Hospital, and his Radiology and Nuclear Medicine residencies at the University of Southern California.

Core Faculty: Peter D. Giuliano, MD

Double Boarded Diagnostic Radiologist and Nuclear Medicine Physician

Peter D. Giuliano, MD, is the  Chair of the Department of Radiology at Hoag Memorial Hospital Presbyterian.  He specializes in Nuclear Medicine and Body Imaging.  He is also the vice president of Newport Harbor Radiology and serves as an executive committee member.

Among his many professional activities, he is a member of the Physicians for Social Responsibility, American Medical Student Association, and the American College of Radiology.

Dr. Giuliano completed his medical degree at Loyola Stritch University of Medicine, an internship at Roger Williams Hospital, his Radiology residency at Brown University and his nuclear medicine fellowship at UCLA.   

Core Faculty: Ryan P. Reddy, MD

Physician, Molecular Imaging and Therapy, Hoag Family Cancer Institute

Dr. Reddy is double-boarded in diagnostic radiology and nuclear medicine. He is an expert at complex molecular therapy and an international speaker on Somatostatin Receptor-targeted therapy for patients with neuroendocrine tumors. He completed his fellowship at the Harvard Joint Program in Nuclear Medicine and was junior faculty at Memorial Sloan Kettering Cancer Center before being recruited to Hoag. He received his medical degree from Texas A&M University.

Director of Medical Education

Patty Y. Huang, MD, MPH

Patty Huang, MD, MPH, serves as Medical Director of the Institutional Education Department at Hoag and practices as a hospitalist for Pacific Hospitalist Associates in Newport Beach. Board-certified in internal medicine, she is Immediate Past Chief of Staff at Hoag, having served in the Chief role from 2021-2022. Dr. Huang earned her medical degree from New York University School of Medicine and completed her internship and residency at Harbor-UCLA Medical Center. She completed a health services research fellowship at UCLA and the Los Angeles VA Medical Center. Dr. Huang also earned her master’s degree in public health from the University of California, Los Angeles. A member of the American College of Physicians and the Society of Hospital Medicine, Dr. Huang has served in numerous committees and advisory roles since joining Hoag in 2006.